Sort   by:  
 Page size 
HIV-1 infected patients virally suppressed by antiviral treatment harbor a persistent reservoir of replication competent latent HIV-1 infected cells, which constitute the main roadblock to a cure. A main strategy for HIV cure aims to stimulate viral gene expression in latently infected cells so that...
ORGANISM(S): Homo sapiens (Human) 
2022-05-31 | PXD032975 | Pride
CaptureSeq to study HIV-1 transcription after reversal of latency
HIV-1 latency results from a combination of tightly regulated molecular processes that act at distinct steps of HIV-1 gene expression. In an effort to elucidate the molecular players that govern viral latency, we previously performed a dCas9 chromatin immunoprecipitation coupled with mass spectromet...
ORGANISM(S): Homo sapiens (Human) 
2024-06-16 | PXD043334 | Pride
A major challenge to the current efforts to cure HIV-1 infection is the persistence of latent viruses. Addressing this challenge hinges on unraveling the intricate interplay between the host and viral factors that are key for HIV-1 latency. Current antiretroviral agents effectively prevent actively ...
ORGANISM(S): Homo Sapiens 
2025-03-25 | PXD062187 |
Gene expression changes following latency reversal agents screening in a cellular model of HIV-1 latency
Catchet-MS identifies IKZF1-targeting Thalidomide analogues as novel HIV-1 latency reversal agents
The goal of this study was to utilize CaptureSeq to be able to measure HIV-1 transcription after reversal of latency in primary cells from antiretroviral-treated HIV-1 infected individuals.
ORGANISM(S): Homo sapiens 
2021-06-01 | GSE152377 | GEO
Despite successful combination antiretroviral therapy (cART), persistent low-grade immune activation together with inflammation and toxic antiretroviral drugs can lead to long-lasting metabolic flexibility and adaptation in people living with HIV (PLWH). Our study investigated alterations in the pla...
ORGANISM(S): Homo sapiens (Human) 
2021-11-24 | PXD028531 | Pride
Interleukin-2 is a potent latency reversal agent in people with treated HIV-1
Blocking Host Factors IAP and DDX3 Reverse HIV-1 Latency and Restore Apoptosis Vulnerability of the HIV-1 reservoir
Sort   by:  
 Page size